Supernus Pharmaceuticals Inc’s recent filing unveils that its SVP, Chief Medical Officer Rubin Jonathan unloaded Company’s shares for reported $36292.0 on Feb 21 ’25. In the deal valued at $39.15 per share,927 shares were sold. As a result of this transaction, Rubin Jonathan now holds 7,853 shares worth roughly $0.25 million.
Then, Bhatt Padmanabh P. sold 9,477 shares, generating $376,237 in total proceeds. Upon selling the shares at $39.70, the Sr. VP of IP, CSO now owns 10,149 shares.
Before that, Bhatt Padmanabh P. sold 2,573 shares. Supernus Pharmaceuticals Inc shares valued at $101,942 were divested by the Sr. VP of IP, CSO at a price of $39.62 per share. As a result of the transaction, Bhatt Padmanabh P. now holds 10,149 shares, worth roughly $0.32 million.
Cantor Fitzgerald downgraded its Supernus Pharmaceuticals Inc [SUPN] rating to a Neutral from a an Overweight in a research note published on February 19, 2025; the price target was decreased to $36 from $57. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in early January with a ‘”an Overweight”‘ rating. Piper Sandler also remained covering SUPN and has decreased its forecast on September 11, 2024 with a “Neutral” recommendation from previously “an Overweight” rating.
Price Performance Review of SUPN
On Tuesday, Supernus Pharmaceuticals Inc [NASDAQ:SUPN] saw its stock fall -3.27% to $31.68. Over the last five days, the stock has lost -4.15%. Supernus Pharmaceuticals Inc shares have fallen nearly -12.39% since the year began. Nevertheless, the stocks have fallen -7.12% over the past one year. While a 52-week high of $40.28 was reached on 02/05/25, a 52-week low of $25.53 was recorded on 02/26/25. SMA at 50 days reached $34.90, while 200 days put it at $33.51.
Levels Of Support And Resistance For SUPN Stock
The 24-hour chart illustrates a support level at 31.15, which if violated will result in even more drops to 30.63. On the upside, there is a resistance level at 32.43. A further resistance level may holdings at 33.19. The Relative Strength Index (RSI) on the 14-day chart is 40.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.76%. Stochastics %K at 51.05% indicates the stock is a holding.
How much short interest is there in Supernus Pharmaceuticals Inc?
A steep rise in short interest was recorded in Supernus Pharmaceuticals Inc stocks on 2025-03-14, dropping by -0.68 million shares to a total of 5.03 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 5.72 million shares. There was a decline of -13.54%, which implies that there is a negative sentiment for the stock.
